Oruka Therapeutics’ (ORKA) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued to investors on Thursday,Benzinga reports. Wedbush currently has a $165.00 target price on the stock.

ORKA has been the topic of several other research reports. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Guggenheim reiterated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $128.91.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $84.46 on Thursday. Oruka Therapeutics has a 1 year low of $15.00 and a 1 year high of $115.51. The firm has a market capitalization of $5.59 billion, a PE ratio of -41.61 and a beta of -0.34. The stock has a fifty day moving average of $96.67 and a two-hundred day moving average of $75.75.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts predict that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the sale, the insider owned 31,771 shares of the company’s stock, valued at $2,935,004.98. This trade represents a 20.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 122,950 shares of company stock valued at $11,528,806 over the last three months. Company insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of ORKA. Algert Global LLC raised its holdings in shares of Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares during the period. Nykredit A S purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $29,000. AlphaCentric Advisors LLC lifted its position in shares of Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after acquiring an additional 626 shares in the last quarter. Orion Capital Management LLC acquired a new position in Oruka Therapeutics in the 2nd quarter worth approximately $91,000. Finally, PNC Financial Services Group Inc. boosted its stake in Oruka Therapeutics by 119.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after purchasing an additional 1,736 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Positive psoriasis data: ORKA-001 produced deeper psoriasis clearance at Week 28 in the EVERLAST-A Phase 2a study, supporting the durability of the treatment’s efficacy. Analysts said the therapy maintains a competitive profile. ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
• Positive Sentiment: Analyst support remains strong: Wedbush reaffirmed an “Outperform” rating with a $165 price target, while HC Wainwright reiterated its “Buy” rating and $120 target. Additional analyst commentary characterized ORKA as a bullish healthcare opportunity. Wedbush Rating
• Positive Sentiment: Pipeline advancing: Oruka provided an update on its ongoing ORKA-002 hidradenitis suppurativa study, a randomized, double-blind, placebo-controlled clinical trial. Progress in a second indication could broaden the company’s future commercial opportunity. ORKA-002 Trial Progress
• Neutral Sentiment: Short-interest data is inconclusive: A report listed short interest at zero shares and a zero-day short-interest ratio as of September 24, suggesting the data may be incomplete or anomalous rather than signaling a meaningful change in bearish positioning.
• Negative Sentiment: Safety disclosures offset efficacy gains: ORKA shares weakened even after the positive Week 28 results, with safety information apparently prompting investor caution. The reaction indicates that market participants may need more clarity on the treatment’s benefit-risk profile before assigning greater value to the program. Oruka’s Psoriasis Treatment Maintains Competitive Profile

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.